CryoLife

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment provides cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

CryoLife, Inc. (CRY) CEO Pat Mackin on Q1 2020 Results - Earnings Call Transcript

CryoLife's (CRY) On-X AAP completes the company's On-Xs heart valve portfolio.

CryoLife Wins CE Mark, Boosts Mechanical Valve Foothold in EU

CryoLife, Inc. (CRY) CEO Pat MacKin on Q4 2019 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of 42.86% and -4.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Tops Q4 Earnings Estimates

Braskem

Etsy

FirstService

Carrols Restaurant Group

Figuring out bloated toxic stocks on a regular basis and discarding them at the right time is the key to successful investing.

5 Toxic Stocks to Disown or Play Short to Book Profits

CryoLife, Inc. (CRY) CEO Pat MacKin on Q3 2019 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of 50.00% and -1.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Q3 Earnings Top Estimates

CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.

CryoLife Enters Agreement With Endospan for Aortic Stent

Calix

Covanta Holding Corp

GTT Communications

Overhyped toxic stocks are vulnerable to external shocks and burdened with huge amount of debt.

4 Toxic Stocks to Abandon or Sell Short for Solid Gains

CryoLife's (CRY) CEO Pat Mackin on Q2 2019 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of 37.50% and 0.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Surpasses Q2 Earnings and Revenue Estimates

CryoLife's (CRY) CEO Patrick Mackin on Q1 2019 Results - Earnings Call Transcript

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CryoLife (CRY) Reports Next Week: Wall Street Expects Earnings Growth

News for CryoLife Stock (CRY)